MCF Advisors’s Akebia Therapeutics AKBA Stock Holding History

MCF Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,913	Closed	-$40K	–	462
2020 Q2	$40K	Hold	2,913	–	–	0.01%	241
2020 Q1	$22K	Hold	2,913	–	–	﹤0.01%	292
2019 Q4	$18K	Hold	2,913	–	–	﹤0.01%	334
2019 Q3	$11K	Hold	2,913	–	–	﹤0.01%	357
2019 Q2	$14K	Buy	2,913 +1,000	+52%	+$5.69K	﹤0.01%	335
2019 Q1	$16K	Hold	1,913	–	–	﹤0.01%	317
2018 Q4	$11K	Hold	1,913	–	–	﹤0.01%	346
2018 Q3	$17K	Hold	1,913	–	–	﹤0.01%	314
2018 Q2	$19K	Hold	1,913	–	–	﹤0.01%	284
2018 Q1	$18K	Buy	1,913 +1,000	+110%	+$14K	﹤0.01%	295
2017 Q4	$14K	Hold	913	–	–	﹤0.01%	314
2017 Q3	$18K	Hold	913	–	–	﹤0.01%	307
2017 Q2	$13K	Hold	913	–	–	﹤0.01%	345
2017 Q1	$8K	Hold	913	–	–	﹤0.01%	364
2016 Q4	$10K	Hold	913	–	–	﹤0.01%	311
2016 Q3	$8K	Hold	913	–	–	﹤0.01%	340
2016 Q2	$7K	Hold	913	–	–	﹤0.01%	373
2016 Q1	$8K	Hold	913	–	–	﹤0.01%	344
2015 Q4	$12K	Hold	913	–	–	﹤0.01%	304
2015 Q3	$9K	Hold	913	–	–	﹤0.01%	327
2015 Q2	$9K	Hold	913	–	–	﹤0.01%	337
2015 Q1	$10K	Hold	913	–	–	﹤0.01%	321
2014 Q4	$11K	Hold	913	–	–	﹤0.01%	298
2014 Q3	$18K	Hold	913	–	–	0.01%	258
2014 Q2	$18K	Buy	+913	New	+$22K	0.01%	252

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCF Advisors's AKBA Position: Q3 2020 in Review

MCF Advisors sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 2,913 shares — an estimated $40K sold.

MCF Advisors first reported a position in AKBA in Q2 2014 and held it in 25 quarters. The position peaked at $40K in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

MCF Advisors reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
MCF Advisors sold 2,913 Akebia Therapeutics shares in Q3 2020, an estimated $40K.
MCF Advisors first reported a position in Akebia Therapeutics in Q2 2014 and held it in 25 quarters.
MCF Advisors's Akebia Therapeutics position peaked at $40K in Q2 2020.
164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on MCF Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.